RIGEL PHARMACEUTICALS, INC.
Patent Owner
Stats
- 367 US PATENTS IN FORCE
- 10 US APPLICATIONS PENDING
- Mar 20, 2018 most recent publication
Details
- 367 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 12,106 Total Citation Count
- Apr 01, 1994 Earliest Filing
- 112 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0064,646 METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINENov 09, 17Mar 08, 18[A61K, A61M]
2017/0369,476 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDSJun 26, 17Dec 28, 17[C07D]
2017/0291,909 Prodrugs of 2,4-Pyrimidinediamine Compounds and Their UsesNov 23, 16Oct 12, 17[C07F, C07D]
2017/0158,683 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAYFeb 22, 17Jun 08, 17[C07F, C07D, C07B]
2017/0042,891 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCERMar 22, 16Feb 16, 17[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9920041 Compositions and methods for inhibition of the JAK pathwayFeb 22, 17Mar 20, 18[C07F, C07D, C07B]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0087,673 METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDSAbandonedSep 26, 14Mar 26, 15[A61K, C07D, G01N]
2014/0213,555 COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASESAbandonedJan 24, 14Jul 31, 14[C07F, C07D]
2013/0310,278 Multiparameter FACS Assays to Detect Alterations in Cellular Parameters and to Screen Small Molecule LibrariesAbandonedNov 07, 12Nov 21, 13[G01N]
2013/0281,446 XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINEAbandonedJun 18, 13Oct 24, 13[A61K]
2013/0102,596 METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINEAbandonedOct 19, 12Apr 25, 13[A61K, A61P, A61M, B65B]
2012/0253,039 Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine CompoundsAbandonedApr 09, 12Oct 04, 12[C07D]
2011/0130,415 PROTEIN KINASE C INHIBITORS AND USES THEREOFAbandonedDec 01, 10Jun 02, 11[A61K, C12Q, C07D, C12N, A61P]
2011/0104,662 Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIVAbandonedNov 17, 10May 05, 11[C12Q]
2011/0028,503 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAYAbandonedJul 28, 10Feb 03, 11[A61K, C07D, A61P]
2011/0015,155 Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their UsesAbandonedJul 16, 10Jan 20, 11[A61K, C07F, C07D, A61P]
7714137 Pyridyl substituted heterocycles useful for treating or preventing HCV infectionExpiredDec 20, 07May 11, 10[C07D]
2010/0041,678 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERSAbandonedAug 13, 09Feb 18, 10[A61K]
2009/0306,028 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERSAbandonedJun 12, 09Dec 10, 09[A61K, A61P]
7598050 Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 proteinExpiredDec 08, 06Oct 06, 09[A61K, G01N, C07K]
2009/0176,202 Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIVAbandonedMar 24, 08Jul 09, 09[C12Q, C12N]
2009/0093,494 4-Pyrimidineamine Compounds And Uses As Anti-Proliferative AgentsAbandonedDec 12, 08Apr 09, 09[A61K, C07D, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.